60 Cases of Chronic Systolic Heart Failure Treatment.docVIP

 PAGE \* MERGEFORMAT 5 60 Cases of Chronic Systolic Heart Failure Treatment [Paper Keywords] neuroendocrine antagonist; systolic heart failure [Abstract] Objective: To explore the neuroendocrine antagonist (ACEI, β -receptor blocker) on chronic systolic heart failure. Methods: 60 patients with chronic systolic heart failure patients, in general, based on the treatment of neuroendocrine antagonist was added to observe the cardiac function to improve the situation, 3 years, mortality and re-hospitalization rates. Results: The significant improvement in 40 cases, accounting for 66.7%; improvement in 8 cases, accounting for 13.3%; total effective rate was 80.0%; three years, re-hospitalization due to worsening heart failure in 10 cases, accounting for 16.7%; 3 years, 6 died, accounting for 10.0%; healed in 3 cases, accounting for 5.0%; deterioration in 3 cases, accounting for 5.0%. Conclusion: Chronic neuroendocrine antagonists can improve clinical outcome in patients with systolic heart failure and improve cardiac function and reduce re-hospitalization rates and mortality. Chronic systolic heart failure is caused by a variety of reasons the terminal stage of heart disease. Has long been considered chronic systolic heart failure can not stop progress of the disease and can not reduce mortality. However, since 2002, China issued recommendations for treatment of chronic systolic heart failure, I have homes in 60 cases of the general treatment of such patients on the basis of neuroendocrine antagonist was added, to achieve a satisfactory effect, significantly improved clinical outcomes, are summarized as follows Treatment : A clinical data I choose my hospital in March 2002 ~ December 2005 with chronic systolic heart failure 60 cases, male 50 cases and 10 females, aged 45 to 80 years, with an average 62.5 years of age. Course of 1 to 16 years, with an average duration of 8.5 years. Ischemic cardiomyopathy 48 cases (80.0%), dilated cardiomyopathy in 6 case